2. Search Result
Search Result
Results for "

Regorafenib

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10331
    Regorafenib
    Maximum Cited Publications
    47 Publications Verification

    BAY 73-4506

    		 VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie Cancer
    Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .
    <em>Regorafenib</em>
  • HY-10331S
    Regorafenib-d3

    BAY 73-4506-d3
    Regorafenib-d3 is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor[1].
    <em>Regorafenib</em>-d3
  • HY-10331A
    Regorafenib monohydrate
    Maximum Cited Publications
    47 Publications Verification

    BAY 73-4506 monohydrate

    		 VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie Cancer
    Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .
    <em>Regorafenib</em> monohydrate
  • HY-10331B
    Regorafenib mesylate

    BAY 73-4506 mesylate

    		 VEGFR PDGFR RET Raf c-Kit FGFR Autophagy Tie Cancer
    Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity .
    <em>Regorafenib</em> mesylate
  • HY-108226S
    Regorafenib N-oxide and N-desmethyl (M5)-d3

    		Isotope-Labeled Compounds Others
    Regorafenib N-oxide and N-desmethyl (M5)-d3 is deuterium labeled Regorafenib N-oxide and N-desmethyl (M5).
    <em>Regorafenib</em> N-oxide and N-desmethyl (M5)-d3
  • HY-108226S1
    Regorafenib N-oxide and N-desmethyl (M5)-13C6

    		Isotope-Labeled Compounds Others
    Regorafenib N-oxide and N-desmethyl (M5)- 13C6 is the 13C-labeled Regorafenib N-oxide and N-desmethyl (M5)[1].
    <em>Regorafenib</em> N-oxide and N-desmethyl (M5)-13C6
  • HY-13308
    Regorafenib Hydrochloride
    Maximum Cited Publications
    47 Publications Verification

    BAY 73-4506 hydrochloride

    		 VEGFR Autophagy PDGFR Raf RET Cancer
    Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively .
    <em>Regorafenib</em> Hydrochloride
  • HY-10331S1
    Regorafenib-13C,d3

    BAY 73-4506-13C,d3

    		 VEGFR Autophagy PDGFR Raf RET Cancer
    Regorafenib- 13C,d3 is the 13C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.
    <em>Regorafenib</em>-13C,d3
  • HY-120422S
    N-Desmethyl Regorafenib-d3

    		Isotope-Labeled Compounds Others
    N-Desmethyl Regorafenib-d3 is deuterium labeled BAY-751098.
    N-Desmethyl <em>Regorafenib</em>-d3
  • HY-I0678
    Regorafénib N-oxyde (M2)

    		Drug Metabolite PDGFR Cancer
    Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
    Regorafénib N-oxyde (M2)
  • HY-I0678S1
    Regorafénib N-oxyde (M2)-13C,d3

    		Drug Metabolite Cancer
    Regorafénib N-oxyde (M2)- 13C,d3 is the 13C- and deuterium labeled Regorafénib N-oxyde (M2). Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
    Regorafénib N-oxyde (M2)-13C,d3
  • HY-I0678S
    Regorafénib N-oxyde-d3 (M2)

    		PDGFR Drug Metabolite Cancer
    Regorafénib N-oxyde-d3(M2) is the deuterium labeled Regorafénib N-oxyde M2[1]. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[2].
    Regorafénib N-oxyde-d3 (M2)
  • HY-149228
    USP28-IN-2

    		Deubiquitinase Cancer
    USP28-IN-2 is a USP28 inhibitor (IC50=0.3 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-2 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-2 also decreases the ankyrase-1/2 level in vitro. USP28-IN-2 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331) .
    USP28-IN-2
  • HY-149229
    USP28-IN-3

    		Deubiquitinase Cancer
    USP28-IN-3 is a USP28 inhibitor (IC50=0.1 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-3 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-3 also decreases the ankyrase-1/2 level in vitro. USP28-IN-3 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331) .
    USP28-IN-3
  • HY-149230
    USP28-IN-4

    		Deubiquitinase Cancer
    USP28-IN-4 is a USP28 inhibitor (IC50=0.04 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-4 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-4 also decreases the ankyrase-1/2 level in vitro. USP28-IN-4 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331) .
    USP28-IN-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: